Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women’s Health Business Unit, Accelerating Strategic Expansion
Asieris Pharmaceuticals (Stock code :688176.SH) has announced its set-up of the Women’s Health Business Unit for commercialization. This strategic move is designed to enhance the company’s focus on genitourinary diseases and…
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialise OHB-607, a potentially transformative neonatal therapy
Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceuticals and healthcare group, and Oak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company, today announced the execution of an…
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson’s Disease in the European Union
AbbVie (NYSE: ABBV) today announced the launch of PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary…
Indira IVF Commences Global Aspirations, Enters International Fertility Market
Indira IVF, India’s largest network of infertility treatment hospitals, has announced its international foray with the inauguration of its hospital in Kathmandu, Nepal. This marks the organisation’s first move beyond…
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio
On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd.…
Mindful Therapy Group Expands Leadership Team to Drive Innovation & Support Growth
Mindful Therapy Group (Mindful), a collaborative network of over 1,000 licensed, independent mental health clinicians, today announced the addition of two new executive leaders. Stephen Oshyn joins as Vice President of…
Clinical trial on Ambio Life Sciences’ ibogaine treatment for Navy SEALs with traumatic brain injury published in Nature Medicine
Today, Nature Medicine published the results of a clinical trial, in which 30 former Navy SEALs were administered ibogaine at Ambio Life Sciences in Mexico to treat traumatic brain injuries, which they developed during their military…
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to…
SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease
SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of innovative therapies for kidney diseases, today announces its acquisition by Novartis, a global medicines company. Following the…
Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory Conditions
Real-world evidence (RWE) leader, Target RWE, today announced its innovative Precision Medicine Platform, a robust biorepository of 150,000+ samples collected along the patient journey from over 10,000 enrolled patients with 5+…